Home > Resources > Whitepapers > Cell Therapy Logistics

Cell Therapy Logistics

February 11, 2019

Much of the discussion in the cell therapy industry today focuses on the complexity of manufacturing and the unique characteristics of each dose. However, the ultimate success of a cell therapy clinical trial rests on the ability to deliver a viable, potent product to the patient. Ensuring this living drug is delivered to the right patient at the right time, location, and the temperature is essential to patient safety and product effectiveness. Having a sound logistics strategy is critical to achieving this goal.

Spotlight

Central Health

Central Health is the second largest health region in Newfoundland and Labrador, providing health and community services to approximately 20 per cent of the province’s population. Our 94,000 clients, patients, residents, and their families live in 177 communities in a region that extends from Charlottetown in the east, Fogo Island in the north, Harbour Breton in the south, to Baie Verte in the west.

OTHER WHITEPAPERS

Could DNA be the next big thing in data storage?

whitePaper | August 19, 2021

DNA storage technology is advancing rapidly. Atos is closely monitoring the development of this technology in the hope that future developments will make it a scalable, cost effective and crucially a decarbonized alternative to today’s carbon intensive technologies.

Antibodies to Viral Vectors Responding to Demands toSimplify Progress in Bioprocessing

whitePaper | March 16, 2023

Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.

Advanced Biopharmaceutical Manufacturing: An Evolution Underway

whitePaper | June 5, 2022

The past decade has seen a significant shift in the nature of the products being manufactured and sold by the innovative biopharmaceutical (biopharma) industry. The global biopharmaceutical portfolio of today reflects increased therapeutic competition, a greater prevalence of large molecule drugs, expansion in the number of personalized or targeted products, and a rise of treatments for many orphan diseases.

rFC adoption for bacterial endotoxin testing

whitePaper | December 7, 2022

OVER THE LAST 20 years, the worldwide value of traded pharmaceutical goods has grown six‑fold, from $113 billion in 2000 to $629 billion in 2019.1 Yet amid such robust growth comes risk to supply chain security as manufacturers become increasingly dependent on a global network of suppliers